Viking Therapeutics' VK2735 Maintains 90% of Weight Loss on Monthly Dosing Schedule

Patients managing obesity now have clinical evidence that they can step down their medication to a single monthly injection without immediately regaining the weight they lost. In a trial concluding this September, participants who switched to a once-a-month dose of the experimental dual-agonist VK2735 retained up to 90 percent of their prior weight loss, establishing a realistic off-ramp from the weekly injection schedules that currently dominate obesity treatment. This shift fundamentally alters the long-term outlook for individuals who have achieved their target weight but fear the rapid rebound associated with stopping treatment entirely.[2][3]

The data, released on September 22, 2026, by Viking Therapeutics, tracks patients who had already completed an initial intensive weight-loss phase. Instead of continuing the weekly shots required by current market standards, these participants were shifted to maintenance regimens consisting of either every-other-week or monthly doses. Researchers closely monitored their body mass, metabolic markers, and overall tolerability over the subsequent months to determine if the reduced frequency could sustain the physiological changes induced during the active weight-loss period.[4][6]

The results demonstrated that the monthly dosing cohort kept off the vast majority of the weight, defying expectations that a four-week gap between doses would lead to significant metabolic regression. "Viking achieves a maintenance trifecta," noted analysts at BioSpace, pointing out that the drug exceeded expectations for efficacy, tolerability, and dosing convenience. Maintaining 90 percent of the initial weight loss on just twelve doses a year represents a major physiological breakthrough in how the body processes these synthetic hormones.[2]

VK2735 targets both GLP-1 and GIP receptors, utilizing the same dual-agonist mechanism popularized by Eli Lilly's Zepbound. However, the extended half-life demonstrated in this specific trial suggests the Viking compound remains active in the human body significantly longer than current market leaders. By binding to these receptors and slowing gastric emptying while simultaneously signaling satiety to the brain over a prolonged period, the drug prevents the sudden spikes in appetite that typically derail weight maintenance efforts. This sustained receptor activation is what allows patients to go four full weeks without experiencing the intense hunger cues that usually follow a missed weekly dose.[1][3]

For patients, the practical difference between 52 injections a year and 12 injections a year is transformative. Weekly dosing often leads to severe injection fatigue, localized skin reactions at the injection site, and an eventual drop-off in compliance. When patients miss their weekly doses, they typically experience rapid weight regain, erasing months of progress. A monthly schedule aligns obesity management more closely with routine preventative care, allowing patients to receive their dose during a standard clinic visit rather than managing weekly home injections.[3][5]

Financial markets reacted immediately to the September data drop, recognizing the commercial threat this poses to the current duopoly in the weight-loss sector. Quartz reported that the robust maintenance data "fuels bets it can rival Lilly's Zepbound," as institutional investors reappraised Viking's position in a global market projected to exceed $100 billion by the end of the decade. A drug that offers the same peak weight loss but requires a fraction of the maintenance effort instantly becomes a preferred option for both insurers and patients.[1][4]

The clinical trial also closely monitored side effects during the step-down phase, a critical metric for any drug intended for lifelong use. Nausea, vomiting, and gastrointestinal distress—the most common hurdles during the initial weight-loss period—were markedly lower during the monthly maintenance phase. Because the patients' bodies had already acclimated to the dual-agonist mechanism, the monthly maintenance doses were absorbed with minimal disruption to their daily lives, making the drug significantly easier to tolerate over a multi-year horizon.[3][6]

The next step for Viking Therapeutics involves advancing VK2735 into late-stage Phase 3 clinical trials to confirm these maintenance figures in a much larger, more demographically diverse population. Researchers will need to prove that the 90 percent retention rate holds steady across different age groups, starting weights, and metabolic profiles. If those numbers hold through the final phases of testing, the FDA could see a filing that fundamentally shifts how doctors prescribe and manage long-term obesity medications.[2][5]